PUBLISHER: IMARC | PRODUCT CODE: 1347759
PUBLISHER: IMARC | PRODUCT CODE: 1347759
Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2023-2028
Market Overview:
The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
Lung Cancer Therapeutics Market Trends:
The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on therapy, cancer type, and distribution channel.
Therapy Insights:
Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Others
Immunotherapy
Durvalumab
Nivolumab
Atezolizumab
Pembrolizumab
Radiation Therapy
External Beam
Internal Beam
Systemic
Chemotherapy
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.
Cancer Type Insights:
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Distribution Channel Insights:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for lung cancer therapeutics. Some of the factors driving the North America lung cancer therapeutics market included the increasing prevalence of lung cancer, rising awareness among individuals about the benefits of early diagnosis and treatment, technological advancements in treatment procedures, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
- What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
- What are the key regional markets?
- Which countries represent the most attractive lung cancer therapeutics market?
- What is the breakup of the market based on the therapy?
- Which is the most attractive therapy in the lung cancer therapeutics market?
- What is the breakup of the market based on the cancer type?
- Which is the most attractive cancer type in the lung cancer therapeutics market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the lung cancer therapeutics market?
- What is the competitive structure of the global lung cancer therapeutics market?
- Who are the key players/companies in the global lung cancer therapeutics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Lung Cancer Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Therapy
- 6.1 Targeted Therapy
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Bevacizumab
- 6.1.2.2 Dabrafenib/Trametinib
- 6.1.2.3 Erlotinib Hydrochloride
- 6.1.2.4 Osimertinib
- 6.1.2.4 Others
- 6.1.2 Market Forecast
- 6.2 Immunotherapy
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Durvalumab
- 6.2.2.2 Nivolumab
- 6.2.2.3 Atezolizumab
- 6.2.2.4 Pembrolizumab
- 6.2.2 Market Forecast
- 6.3 Radiation Therapy
- 6.3.1 Market Trends
- 6.3.2 Key Segment
- 6.3.2.1 External Beam
- 6.3.2.2 Internal Beam
- 6.3.2.3 Systemic
- 6.3.2 Market Forecast
- 6.4 Chemotherapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Cancer Type
- 7.1 Non-small Cell Lung Cancer (NSCLC)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Small Cell Lung Cancer (SCLC)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Amgen Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 AstraZeneca Plc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Boehringer Ingelheim International GmbH
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Bristol-Myers Squibb Company
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Daiichi Sankyo Company Limited
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Eli Lilly and Company
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 GSK PLC
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Merck & Co. Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Novartis AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Pfizer Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.12 Roche Holding AG
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.13 Takeda Pharmaceutical Company Limited
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.1 AbbVie Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
List of Figures
- Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
- Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Billion US$), 2017-2022
- Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
- Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2022
- Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2022
- Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2022
- Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2022
- Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2022
- Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
- Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
- Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2022 & 2028
- Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
- Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2023-2028
- Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
- Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
- Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
- Table 7: Global: Lung Cancer Therapeutics Market: Key Players
